Chris is an experienced patent litigator who specialises in advising life sciences companies on patent and SPC disputes. He also advises clients in the Tech, Media and Comms sector on disputes involving technical subject-matter.

His strong academic background in chemistry has allowed Chris to represent clients in the biotech and pharma sectors in some of the most complex multi-jurisdictional patent disputes brought before the English courts. Chris has extensive experience of preparing experts and fact witnesses for giving evidence at trial. He has experience of co-ordinating and harmonising strategy with litigation teams in international jurisdictions including the United States and across Europe (including parallel EPO opposition proceedings).

Chris has been praised by clients for his “encyclopedic knowledge”, his responsiveness, and his ability to “grasp points very rapidly indeed”. He is recognised in key legal and IP directories, including as a patent litigation ‘Rising Star’ by Managing IP's IP Stars in 2019/20 and 2018/19, and by Legal 500 as “good at technical matters” (2017/18) and a “key figure” in the pharmaceutical and biotechnology sectors (2016/17).

Key cases on which Chris has acted include:

  • Merck Sharp & Dohme v Wyeth (pneumococcal vaccines)
  • Eli Lilly v Genentech (IL-17 antibodies/inflammatory diseases)
  • Astex Therapeutics v AstraZeneca (BACE inhibitors/Alzheimer's Disease)
  • GSK v Wyeth (meningitis B vaccines)
  • Semafone v Eckoh (secure payment systems)
  • Philips v Nintendo (human-computer interaction)
  • HTC v Apple (smartphones)

Chris joined Osborne Clarke as an Associate Director in November 2019 from IP boutique Marks & Clerk Law. Before that, he worked for Freshfields and Baker McKenzie. He qualified as a solicitor in 2009.

Chris has a BSc Joint Honours degree in Chemistry and Law from the University of Bristol (achieving First Class Honours in Chemistry) and a LL.M (with Distinction) in IP Law from UCL.